Low-Dose Naltrexone Medicaid Coverage by State Tier (2026 Guide)

Why Medicaid Does Not Cover Compounded LDN

Medicaid coverage of any drug requires that the product appear on a state Preferred Drug List (PDL) or qualify for a federal rebate under the Medicaid Drug Rebate Program (MDRP). Compounded medications, by definition, are not FDA-approved drug products and therefore are excluded from MDRP rebates. That exclusion is the structural barrier.

The FDA classifies 503A compounding pharmacies, the type that dispenses most LDN, as patient-specific operations exempt from new drug approval requirements but also ineligible for the commercial distribution that triggers Medicaid rebate agreements. The FDA's guidance on compounded drugs and the MDRP is summarized in federal statute 42 U.S.C. 1396r-8, which explicitly ties rebate eligibility to an approved New Drug Application (NDA). [1]

The MDRP Exclusion in Plain Terms

Naltrexone 50 mg tablets (Vivitrol injectable form included) carry NDAs and appear on state PDLs for opioid use disorder (OUD) treatment. Those approved products do receive Medicaid reimbursement. Compounded naltrexone at 1.5 to 4.5 mg does not share the NDA, so it cannot piggyback on the same PDL entry.

Off-Label vs. Compounded: A Critical Distinction

A prescriber can write "naltrexone 4.5 mg" as an off-label dose, but Medicaid only reimburses a dispensed, commercially manufactured product. No commercial manufacturer produces naltrexone capsules below 50 mg. That gap is why compounding exists for LDN, and it is precisely the gap that blocks Medicaid reimbursement. [2]

State-by-State Medicaid Tier Classification for LDN (2026)

Because no state lists compounded LDN on its PDL, the tier framework below describes how each state handles the closest available coverage pathway: reimbursement of commercially manufactured naltrexone 50 mg for OUD, and whether the state's compounding policy leaves any theoretical door open for LDN prescriptions.

Tier 1: OUD naltrexone covered, no compounding pathway (majority of states)

Most states, including California, Texas, Florida, Ohio, and Pennsylvania, cover naltrexone 50 mg tablets and Vivitrol 380 mg injection for OUD on their Medicaid PDLs. Prior authorization is required in roughly 34 states per SAMHSA's 2023 Medications for Opioid Use Disorder report. [3] None of these states extend that coverage to compounded low-dose formulations. Patients in Tier 1 states pay full cash price for LDN.

Tier 2: Medicaid managed care with compounding flexibility language

A smaller group of states, including New York, Illinois, and Washington, operate Medicaid managed care organizations (MCOs) that include contract language permitting coverage of compounded drugs when "medically necessary and not commercially available." In theory this language could apply to LDN. In practice, no MCO in these states had approved an LDN claim as of the date of this article's review. Patients should submit a prior authorization request with documented clinical rationale if they are in a Tier 2 state; denial rates are high but an appeal creates a paper trail.

Tier 3: State Medicaid with explicit compounding exclusion policies

Georgia, Mississippi, and Alabama have Medicaid policies that explicitly exclude coverage of compounded drugs except when a commercial equivalent is unavailable AND the prescriber documents a clinical exception. Because no commercial LDN product exists, the second criterion is met by default. The first step is a letter of medical necessity citing peer-reviewed evidence. The 2013 randomized controlled trial by Younger et al. (N=31) in fibromyalgia, published in Pain Medicine, showed a statistically significant reduction in pain scores with naltrexone 4.5 mg vs. Placebo (P<0.001 on 14-week crossover), which can serve as supporting evidence in a PA letter. [4]

Tier 4: Medicaid waiver states (1115 waivers) with expanded formulary authority

States operating approved Section 1115 Medicaid demonstration waivers sometimes gain authority to cover drugs outside the standard MDRP framework. As of 2026, no active 1115 waiver specifically includes LDN. However, states with mental health or chronic pain 1115 waivers, such as Oregon and Colorado, have broader MCO formulary discretion. A prescriber familiar with these waivers could request MCO review. CMS publishes current waiver approvals at CMS.gov/Medicaid waivers. [5]

Verifying Your State PDL Before Filing a Prior Authorization

State PDLs update quarterly. Before spending time on a prior authorization, look up your state's current PDL on the state Medicaid agency website. Search for "naltrexone" in the PDL document. If only the 50 mg commercial product appears, compounded LDN is not covered and a PA request will be denied at the formulary review stage.

How to Get Low-Dose Naltrexone Cheaper: Seven Concrete Options

Most LDN patients pay cash. Prices vary widely based on dose, capsule count, and pharmacy. Here are the seven lowest-cost legal pathways as of early 2026.

1. 503A Compounding Pharmacy Direct Pricing

A 30-day supply of naltrexone 4.5 mg capsules from a 503A pharmacy typically costs $30 to $60. Skip the retail markup by ordering through a pharmacy that has an established relationship with your telehealth provider. Many HealthRX prescriptions are fulfilled at compounding rates below the national average because of volume agreements. Always confirm the pharmacy holds a valid state license and complies with USP 795 standards for non-sterile compounding. [6]

2. Naltrexone 50 mg Tablets Plus Pill Splitter or Liquid Titration

Some prescribers write for commercially manufactured naltrexone 50 mg tablets and instruct patients to crush and dissolve in distilled water to create a 1 mg/mL solution, then measure doses with an oral syringe. This approach eliminates compounding costs entirely. A 30-tablet supply of generic naltrexone 50 mg costs approximately $22 to $35 via GoodRx at major retail pharmacies. The 2020 review by Younger and Parkitny in Frontiers in Psychiatry notes that aqueous LDN formulations are pharmacologically equivalent to capsules in small studies. [7]

3. GoodRx and NeedyMeds on the Base 50 mg Product

GoodRx coupons do not apply to compounded capsules because compounding pharmacies do not participate in GoodRx's pharmacy network. They do apply to commercially manufactured naltrexone 50 mg. If your prescriber is willing to write for the 50 mg tablet with liquid titration instructions, GoodRx can reduce the price to roughly $15 to $22 per month at Costco, Walmart, or Kroger pharmacies. NeedyMeds maintains a database of assistance programs at needymeds.org, though naltrexone manufacturer programs focus on the 380 mg injectable for OUD rather than oral tablets. [8]

4. Telehealth Bundled Pricing

Several telehealth platforms, including HealthRX, bundle the prescriber visit and compounding pharmacy dispensing into a single monthly fee. Bundled pricing removes the separate specialist office visit cost (which can be $150 to $300 without insurance) and passes pharmacy volume discounts to patients. The total monthly cost, including the visit, is often lower than paying separately for a primary care visit plus a local compounding pharmacy.

5. HSA and FSA Accounts

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can pay for LDN when accompanied by a letter of medical necessity from the prescribing physician. The IRS defines qualified medical expenses under IRS Publication 502, which includes prescription drugs. Compounded LDN is a prescription drug, so it qualifies. Submit your prescriber's letter with the FSA reimbursement claim if your FSA administrator requests documentation. [9]

6. Patient Assistance Programs for Related Diagnoses

Naltrexone 50 mg tablets are included in several OUD patient assistance programs, most notably through Amneal Pharmaceuticals. These programs are means-tested and diagnosis-restricted. A patient prescribed LDN for Crohn disease or fibromyalgia would not qualify for an OUD-specific program. For autoimmune indications, the relevant strategy is to verify whether the prescribing diagnosis (e.g., Crohn disease) qualifies the patient for biologics assistance programs and to use LDN as the lower-cost add-on or bridge therapy.

7. Compounding Pharmacy Price Shopping

Prices at 503A compounding pharmacies vary by as much as 40% for the same 4.5 mg capsule product. Call at least three accredited pharmacies (look for PCAB accreditation) and ask for the cash price on a 90-day supply of naltrexone 4.5 mg capsules. A 90-day supply often carries a 10 to 15% discount over monthly fills. Accreditation status can be verified through the Pharmacy Compounding Accreditation Board at pcab.org. [10]

Clinical Evidence Supporting LDN Prescriptions (For Prior Authorization Letters)

If you are attempting a Medicaid prior authorization or appealing a commercial insurance denial, citing specific clinical trial data strengthens the case. Below are the key studies by indication.

Fibromyalgia

The double-blind crossover RCT by Younger et al. (2013, N=31) tested naltrexone 4.5 mg vs. Placebo over 14 weeks each. Fibromyalgia symptoms were reduced by a mean of 30% on LDN compared to 2% on placebo (P<0.001). A follow-up open-label study by the same group (Younger et al., 2014, N=30) found that 57% of participants reported greater than 30% pain reduction at 12 weeks. [4]

Crohn Disease

A pilot RCT by Smith et al. (2011, N=40) published in The American Journal of Gastroenterology tested naltrexone 4.5 mg in pediatric Crohn disease. Response rate was 88% in the naltrexone group vs. 40% in the placebo group. A subsequent adult trial by Smith et al. (2015, N=40) confirmed clinical response in 88% of naltrexone-treated adults vs. 40% placebo (P<0.009). [11]

Multiple Sclerosis

A phase II randomized trial by Cree et al. (2010, N=80) published in the Annals of Neurology tested naltrexone 4.5 mg in progressive MS. The primary endpoint (spasticity composite) was not met, but quality-of-life measures on the MS Quality of Life-54 instrument showed statistically significant improvement at 8 weeks (P<0.04). The trial author noted that "low-dose naltrexone was safe, well tolerated, and showed trends toward improvement in quality of life measures." [12]

Long COVID

A 2022 case series by Brennan Patterson and colleagues, published in MedRxiv (preprint), described 12 patients with long COVID fatigue who reported subjective improvement on naltrexone 1 to 4.5 mg over 8 to 12 weeks. This is preprint-level evidence and does not support a Medicaid coverage argument, but it illustrates the growing off-label interest in LDN. Peer-reviewed long COVID trials are recruiting as of 2026, with NCT05576220 (ClinicalTrials.gov) investigating LDN in post-COVID fatigue syndromes. [13]

Pharmacology: Why Low Doses Work Differently Than Standard Doses

Understanding the mechanism helps explain why a 50 mg commercial tablet cannot simply substitute for a 4.5 mg dose in clinical terms, and why the compounded form is medically distinct.

Transient Opioid Receptor Blockade and Endorphin Rebound

At 50 mg, naltrexone produces sustained opioid receptor blockade for 24 to 72 hours, which is the basis for its FDA-approved OUD indication. At 1.5 to 4.5 mg taken nightly, the receptor blockade lasts only 4 to 6 hours. This shorter blockade is hypothesized to trigger a rebound upregulation of endogenous opioid production, specifically beta-endorphin and met-enkephalin. The hypothesis is supported by preclinical data from Zagon and McLaughlin, who demonstrated opioid growth factor receptor modulation in murine models as early as 1983. [14]

Glial Cell Modulation

A separate mechanism, described in a 2009 review by Younger and Mackey in Pain Medicine, proposes that naltrexone at low doses antagonizes toll-like receptor 4 (TLR4) on microglial cells in the central nervous system. TLR4 signaling drives neuroinflammation. Doses above 5 mg do not appear to produce the same degree of glial modulation, which is why the dose range matters and why the compounded form is not interchangeable with the commercial tablet. [15]

How to Request a Prior Authorization for LDN Under Medicaid or Commercial Insurance

Even when approval is unlikely, filing a prior authorization creates an administrative record and opens the appeals pathway.

Step 1: Confirm Drug and Diagnosis Codes

Your prescriber submits the PA using the NDC for the compounded naltrexone capsules (assigned by the compounding pharmacy) and an ICD-10 diagnosis code appropriate to your condition. Common codes used include M79.7 (fibromyalgia), K50.90 (Crohn disease, unspecified), and G35 (multiple sclerosis).

Step 2: Attach Clinical Literature

Include the Younger et al. 2013 RCT, the Smith et al. 2011 and 2015 Crohn trials, and the Cree et al. 2010 MS trial as attachments. A one-page prescriber letter summarizing why commercially available alternatives (biologics, immunosuppressants) were inadequate or not tolerated strengthens the submission.

Step 3: File a Step Therapy Exception if Needed

Many payers require step therapy, meaning the patient must fail a formulary drug before a non-formulary drug is considered. For fibromyalgia, the step drugs are usually pregabalin (Lyrica) and duloxetine. Document any prior trials of these agents, including doses and durations. Federal law requires that Medicaid managed care plans provide a step-therapy exception process under 42 C.F.R. 438.3. [16]

Step 4: Appeal Every Denial

First-level appeals are reviewed by the plan's medical director. Second-level appeals go to an independent review organization (IRO). Approval rates at IRO level for compounded drugs are low, but documented medical necessity can occasionally prevail when no commercially available alternative exists.

Safety and Prescribing Considerations

LDN is generally well tolerated. The most common adverse effects in clinical trials are vivid dreams and mild sleep disturbance during the first two to four weeks of titration, reported in roughly 37% of patients in the Younger 2014 fibromyalgia cohort. [4]

The absolute contraindication is concurrent use of full opioid agonists. Even at low doses, naltrexone precipitates withdrawal in opioid-dependent patients. A thorough medication reconciliation before prescribing is non-negotiable. The FDA's prescribing information for naltrexone 50 mg (NDA 018-932) states that patients must be opioid-free for a minimum of 7 to 10 days before initiating any naltrexone product. [17]

Liver function monitoring is recommended at baseline and periodically for patients taking doses at or above 50 mg. At doses of 1.5 to 4.5 mg, hepatotoxicity signals have not emerged in clinical trials, but baseline LFTs remain standard practice at HealthRX before initiating therapy.

Can I Use HSA or FSA for Low-Dose Naltrexone?

Yes. LDN qualifies as an HSA/FSA-eligible expense because it is a prescription drug dispensed by a licensed pharmacy. The IRS definition of a qualified medical expense under Section 213(d) of the Internal Revenue Code includes prescription medications. Compounded prescriptions, including compounded naltrexone capsules, are prescription drugs under this definition. [9]

To avoid claim rejection, ask your prescriber to provide a letter of medical necessity that includes your diagnosis, the prescribed drug and dose, and a statement that the medication is prescribed to treat a specific medical condition. Most FSA administrators accept this letter without requiring the drug to be FDA-approved at the prescribed dose. Some HSA-linked debit cards will auto-approve pharmacy charges; others require manual reimbursement with receipts.